Vivimed Labs Ltd
NSE: VIVIMEDLAB BSE: 532660
₹6.26
(3.84%)
Sat, 30 May 2026, 05:38 am
Market Cap548.89M
PE Ratio0
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KCompany History
1988
- The Company was incorporated as Emgi Pharmaceuticals & Chemicals Private Limited on September 22, 1988
1989
- Mr. Santosh Varalwar and Mr. Subhash Varalwar acquired Emgi Pharmaceuticals and Chemicals Limited
- Death of original promoter Mr. A. M. Rao
1991
- Commenced manufacturing of Bulk Drugs
1994
- The Company was converted into a Public Limited Company on April 4, 1994
- Diversification and Expansion of Product mix by adding other APIs viz. Chlorzoxazone (Skeletal disorders), Nalidixic Acid (Anti-diarrheas) and Flucanazole (Anti-fungal)
1995
- Diversification into specialty chemicals by production of Triclosan
1996
- R&D was commenced with facilities having an integrated instrumentation for organic synthesis, Microbiology and pre-formulation studies
1997
- The name of the Company has been changed to Vivimed Labs Limited on April 22, 1997
- Process Innovation of Anti-bacterial and clearance of innovative route of synthesis for Triclosan
- Grant of patent for VIV-20 (Triclosan) by the Indian Patents Office
1998
- Qualified for supply to Unilever's Asian locations after Audit of manufacturing facility by a team of Unilever Plc
- Triclosan customer base expanded to UK, France, Germany as well as domestic market
1999
- Vivimed started production of Triclosan with a very small capacity of 5 MT p.a
2002
- Approved by Unilever group Companies in Asian/Middle & Far East Companies for usage of Enamel Protective Agent manufactured by the Company in their oral care formulations
- Developed Anti-fungal for usage in High-end cosmetic and pre-formulation blends
- Vivimed emerges as a second chemical Company located outside USA/Europe to get the US EPA's registration for Triclosan as 99% ingredient
- Vivimed's Quality Management System gets ISO 9001:2000 certification
2003
- Signed Confidential Sale Agreement with HLL for R&D, scaling up and commercialization of product coded as A123
- Commencement of EMS Audit for ISO 14001 certification
2004
- Introduced new products for anti-dandruff and skin care application
- Triclosan production capacity increased from 225 MT p.a. to 480 MT p.a
- Developed novel synthetic process to manufacture a premium Anti-oxidant and Anti-cancer molecule branded as VINTOX
2005
- The Company has received the State Award for Excellence in Exports (SSI GOLD) from Karnataka State Government for excellence in exports
- The Company has received 1 star export house status in 2005
2009
- Vivimed Labs Ltd has informed BSE that Mr. Y Krishna has been appointed as an Additional Director on the Board of the Company with effect from June 30, 2009
2010
- Vivimed Labs Ltd has appointed Mr. Nixon Patel as an Additional Director of the Company with effect from June 28, 2010
- Mr. Nixon Patel has been appointed as an Independent Director on the Board
2011
- Vivimed Labs Incorporation of Foreign Subsidiaries namely, Vivimed Labs Mauritius Ltd., Mauritius, Vivimed Labs UK Ltd., UK and Vivimed Labs Spain, SL, Spain
- Vivimed Labs has accquired majority Stake in Octtantis Nobel Labs Private Ltd
- Vivimed Labs Acquired equity stake in Klar Sehen Pvt. Ltd
- Vivimed Labs Acquired Uquifa Spain and Uquifa Mexico
2012
- Vivimed launch Nisarg Soapnut at in-cosmetics, Barcelona
- Mr. K. Yugandhar has been appointed as Company Secretary of the company
2013
- Vivimed acquires a US FDA approved formulation manufacturing facility
- Vivimed are Exhibiting at HPCi - Mumbai
2014
- Vivimed receives the PIC/S GMP approval for one of its pharmaceuticals manufacturing facilities in Hyderabad
- Vivimed Labs - Grant of Options under Vivimed Labs ESOS 2010
2016
- Vivimed’s FDF facility in Alathur completed successful USFDA inspection
- Vivimed launch Jarocol Sapphire Blue
2020
- Vivimed Launches its own brand of favipiravir.